Literature DB >> 22166451

Mild cognitive impairment associated with underlying Alzheimer's disease versus Lewy body disease.

Bradley F Boeve1.   

Abstract

The objective of this paper is to compare and contrast the clinical, neuropsychological, and neuroimaging findings in patients with mild cognitive impairment (MCI) associated with underlying Alzheimer's disease (AD) versus Lewy body disease (LBD) pathology. MCI refers to a clinical syndrome with impairment in one or more cognitive domains, with essentially normal performance of activities of daily living. Patients with the amnesic subtype of MCI often develop the dementia syndrome and neuroimaging findings characteristic of AD [e.g., hippocampal atrophy on magnetic resonance imaging (MRI), temporoparietal and posterior cingulate hypometabolism on fluorodeoxyglucose positron emission tomography (FDG-PET), positive uptake on amyloid PET, normal striatonigral uptake on dopamine transporter scanning (DAT), etc.]. In contrast, the MCI syndrome associated with LBD pathology regardless of the coexisting presence or absence of parkinsonism is usually characterized by impairment in the executive and/or visuospatial domains, and the cognitive features are often preceded by REM sleep behavior disorder by many years. There is minimal hippocampal atrophy on MRI, minimal if any cortical uptake on amyloid-PET, and one would predict that hypometabolism would be maximal in the occipital cortex on FDG-PET and uptake would be decreased on DAT. The early data suggests that differentiating underlying AD vs LBD in the MCI phase will be feasible.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2012        PMID: 22166451     DOI: 10.1016/S1353-8020(11)70015-3

Source DB:  PubMed          Journal:  Parkinsonism Relat Disord        ISSN: 1353-8020            Impact factor:   4.891


  18 in total

Review 1.  A quantitative meta-analysis of olfactory dysfunction in mild cognitive impairment.

Authors:  David R Roalf; Madelyn J Moberg; Bruce I Turetsky; Laura Brennan; Sushila Kabadi; David A Wolk; Paul J Moberg
Journal:  J Neurol Neurosurg Psychiatry       Date:  2016-12-30       Impact factor: 10.154

Review 2.  Insulin resistance in Alzheimer's disease.

Authors:  Kelly T Dineley; Jordan B Jahrling; Larry Denner
Journal:  Neurobiol Dis       Date:  2014-09-16       Impact factor: 5.996

3.  Berberine ameliorates rats model of combined Alzheimer's disease and type 2 diabetes mellitus via the suppression of endoplasmic reticulum stress.

Authors:  Wei-Ting Xuan; Han Wang; Peng Zhou; Ting Ye; Hua-Wu Gao; Shu Ye; Jing-Hui Wang; Meng-Lian Chen; Hang Song; Yan Wang; Biao Cai
Journal:  3 Biotech       Date:  2020-07-29       Impact factor: 2.406

4.  MRS in mild cognitive impairment: early differentiation of dementia with Lewy bodies and Alzheimer's disease.

Authors:  Bing Zhang; Tanis J Ferman; Bradley F Boeve; Glenn E Smith; Mandie Maroney-Smith; Anthony J Spychalla; David S Knopman; Clifford R Jack; Ronald C Petersen; Kejal Kantarci
Journal:  J Neuroimaging       Date:  2014-07-15       Impact factor: 2.486

5.  Donepezil improves the cognitive impairment in a tree shrew model of Alzheimer's disease induced by amyloid-β1-40 via activating the BDNF/TrkB signal pathway.

Authors:  Hong Zheng; Shiwei Niu; Hongbin Zhao; Shude Li; Jianlin Jiao
Journal:  Metab Brain Dis       Date:  2018-08-13       Impact factor: 3.584

6.  Brain Activity of Benzoate, a D-Amino Acid Oxidase Inhibitor, in Patients With Mild Cognitive Impairment in a Randomized, Double-Blind, Placebo Controlled Clinical Trial.

Authors:  Hsien-Yuan Lane; Cheng-Hao Tu; Wei-Che Lin; Chieh-Hsin Lin
Journal:  Int J Neuropsychopharmacol       Date:  2021-05-18       Impact factor: 5.176

7.  Rapid eye movement sleep behavior disorder: devising controlled active treatment studies for symptomatic and neuroprotective therapy--a consensus statement from the International Rapid Eye Movement Sleep Behavior Disorder Study Group.

Authors:  C H Schenck; J Y Montplaisir; B Frauscher; B Hogl; J-F Gagnon; R Postuma; K Sonka; P Jennum; M Partinen; I Arnulf; V Cochen de Cock; Y Dauvilliers; P-H Luppi; A Heidbreder; G Mayer; F Sixel-Döring; C Trenkwalder; M Unger; P Young; Y K Wing; L Ferini-Strambi; R Ferri; G Plazzi; M Zucconi; Y Inoue; A Iranzo; J Santamaria; C Bassetti; J C Möller; B F Boeve; Y Y Lai; M Pavlova; C Saper; P Schmidt; J M Siegel; C Singer; E St Louis; A Videnovic; W Oertel
Journal:  Sleep Med       Date:  2013-07-22       Impact factor: 4.842

Review 8.  (123)I-Metaiodobenzylguanidine Myocardial Scintigraphy in Lewy Body-Related Disorders: A Literature Review.

Authors:  Eun Joo Chung; Sang Jin Kim
Journal:  J Mov Disord       Date:  2015-05-31

9.  Cortical Thickness in Dementia with Lewy Bodies and Alzheimer's Disease: A Comparison of Prodromal and Dementia Stages.

Authors:  Frederic Blanc; Sean J Colloby; Nathalie Philippi; Xavier de Pétigny; Barbara Jung; Catherine Demuynck; Clélie Phillipps; Pierre Anthony; Alan Thomas; Fabrice Bing; Julien Lamy; Catherine Martin-Hunyadi; John T O'Brien; Benjamin Cretin; Ian McKeith; Jean-Paul Armspach; John-Paul Taylor
Journal:  PLoS One       Date:  2015-06-10       Impact factor: 3.240

10.  Long COVID: cognitive complaints (brain fog) and dysfunction of the cingulate cortex.

Authors:  Jacques Hugon; Eva-Flore Msika; Mathieu Queneau; Karim Farid; Claire Paquet
Journal:  J Neurol       Date:  2021-06-18       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.